19221-Endometrial Cancer-NA-468

Endometrial Cancer

D9311C00001; GOG-3041; ENGOT-EN10: A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)

  • Details

ClinicalTrials.gov ID: NCT04269200
Diagnosis Type: NA
USOR Number:

  • Address

5050 NE Hoyt St, Suite 256
Portland, OR 97213
P: (503) 239-7767

Search by practice name, trial titles, indicators and specific disease types.